Characterization of COPD Admissions During the First COVID-19 Outbreak

Purpose: Exacerbations of COPD (ECOPD) are a frequent cause of hospitalization that seemed to ameliorate during the COVID outbreak. We aimed to evaluate the clinical characteristics of COPD-related hospital admissions and mortality in relation to the presence of COVID-19. Patients and Methods: We co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of chronic obstructive pulmonary disease 2021-01, Vol.16, p.1549-1554
Hauptverfasser: Cosio, Borja G, Shafiek, Hanaa, Toledo-Pons, Nuria, Iglesias, Amanda, Barcelo, Margalida, Represas-Represas, Cristina, Comeche, Lorena, Catalan, Pablo, Fernandez-Villar, Alberto, Lopez-Campos, Jose Luis, Echave-Sustaeta, Jose, Soler-Cataluna, Juan Jose
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose: Exacerbations of COPD (ECOPD) are a frequent cause of hospitalization that seemed to ameliorate during the COVID outbreak. We aimed to evaluate the clinical characteristics of COPD-related hospital admissions and mortality in relation to the presence of COVID-19. Patients and Methods: We conducted a case-control study of patients admitted in four teaching hospitals throughout Spain between March 15 and April 30, 2020. Hospital admissions of respiratory cause with and without PCR-proven SARS-CoV-2 infection in patients with COPD were evaluated. Baseline and episode-related clinical characteristics were analyzed. Logistic regression analysis was performed to evaluate the risk for mortality. Results: During the study period, 2101 patients were admitted for respiratory worsening, 1200 (57.1%) with COVID-19. A total of 228 (10.8%) were admitted due to COPD worsening, of whom 52 (22.8%) tested positive for COVID-19. COPD patients with COVID-19, when compared to those without COVID-19, were more frequently males with better lung function ([FEV.sub.1] postbronchodilator 71% vs 46% respectively, p
ISSN:1178-2005
1176-9106
1178-2005
DOI:10.2147/COPD.S312493